Urgo and its partners have produced living artificial skin in a laboratory that is ready for grafting, a world first announced by the French group. The project, called Genesis, is now set to move toward clinical trials.
“We are the first in the world to produce artificial skin in a laboratory that is ready for grafting,” said Guirec Le Lous, Urgo’s chairman. He hailed the achievement as “something incredible.” The announcement is expected to be among the most significant at the Choose France summit on November 23, and could be its centerpiece.
Launched in 2021, Genesis brings together Urgo, CNRS, the Center for the Study of Stem Cells (CECS), the French Blood Establishment and Dassault Systèmes. The milestone is the production of living skin ready for grafting; clinical trials still lie ahead.
The total investment stands at €100 million, the largest in Urgo’s history. That funding covers the project from its beginnings through the completion of clinical trials, rather than simply the cost of producing this first skin.
The French government is providing €22.8 million through Bpifrance under the Structural Projects for Competitiveness program, known as PSCP. The Dijon metropolitan authority and the regional government also support the project. Le Lous described public backing as “essential.”
The next step will be the launch of clinical trials. No precise start date has been announced.


